Optimizing hematopoietic recovery following bone marrow transplantation

Journal of Clinical Investigation

Volumn 109, Issue 12, 2002, Pages 1527-1528

  Paquette, Ronald ^a,b   Dorshkind, Kenneth ^b  

^a Divisionof Hematology Oncology Blood and Marrow Transplantation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW TRANSPLANTATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL GROWTH; CELL POPULATION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; NOTE; PRIORITY JOURNAL; PROGENY; STEM CELL;

EID: 0036084140     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215916     Document Type: Note

References (11)

1. Introduction to the haemopoietic system
2. The genetic program of hematopoietic stem cells
3. Purification and characterization of mouse hematopoietic stem cells
4. Human CD34(+) hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis
5. Identification of clonogenic common lymphoid progenitors in mouse bone marrow
6. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
7. Myeloerythroid-restricted progenitors are sufficient to confer rachoprotection and provide the majority of day 8 CFU-S
8. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells
9. Ex vivo expanded unselected peripheral blood progenitor cells reduce posttransplantation neutropenia, thrombocytopenia and anemia in patients with breast cancer
10. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer
11. Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery